EUVIMEDEUVIMED entdecken
Crossref

High-dose-rate (2 fractions of 13.5 Gy) and low-dose-rate brachytherapy as monotherapy in prostate cancer. Long term outcomes and predictive value of nadir prostate-specific antigen

Silvia Rodríguez Villalba, Diana Guevara Barrera, Luis Suso-Martí, Enrique Sanchis-Sánchez, Jose Pérez-Calatayud, Jose Domingo Lago Martín, Francisco Blázquez Molina, Manuel Santos Ortega

Brachytherapy · 2025-03 · 24 (2) · 310-317

DOI: 10.1016/j.brachy.2024.10.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2025-03. Verfasst von Silvia Rodríguez Villalba und 7 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Hospital Clínica Benidorm, Benidorm, Alicante, Spain. Electronic address: atosrodriguez@gmail.com. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms, Prostate-Specific Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This study aims to evaluate the outcomes of patients treated for low-risk (LR) and favorable intermediate risk (FIR) prostate cancer with brachytherapy (BT) in monotherapy with LDR or HDR and its relationship with nadir PSA (nPSA). MATERIALS AND METHODS: We retrospectively analyzed 139 patients (2005-2019) with exclusive LDR (46%. 145/160 Gy) /HDR (54%. 2 implants of 13.5 Gy each separated 10 days). 69% LR and 31% FIR. PSA nadir was grouped into two categories: ≤ 0.2 ng/mL and > 0.2 ng/mL. RESULTS: Median patient age was 69 years (46-84). Seventy-six patients (55%) received androgen deprivation therapy, and 37% received neoadjuvant therapy. Median follow-up period was 90 months. Actuarial biochemical failure-free survival (BFFS), local control (LC), overall survival (OS), and cause-specific survival (CSS) rates for the total cohort were 78%, 87%, 68%, and 98% at 10 years, respectively. BFFS, LC, OS and CSS in nPSA ≤ 0,2 ng/ml was 90%, 96%, 67%, 100% at 10 years respectively, whereas, those with a nPSA > 0.2 ng/ml had a BFFS, LC, OS and CSS of was 37%, 51%, 72%, 90% at 10 years respectively Statistical significance between both groups was reached in BFFS (p=0,000), LC (p=0,000) and CSS (p=0,007)). In the univariate analysis, there was no difference between risk stratification, BT technique, ADT, or the development of bouncing. CONCLUSIONS: Prostate brachytherapy as monotherapy (LDR and HDR) is an effective treatment option for patients with LR and FIR prostate cancer. nPSA ≤0,2 ng/ml is a representative value that provides prognostic information for favorable outcomes in this group of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyProstatic NeoplasmsProstate-Specific AntigenHumansMaleAgedRetrospective StudiesMiddle AgedAged, 80 and overTreatment OutcomeDose Fractionation, RadiationRadiotherapy Dosage

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Radiation Oncology Department, Hospital Clínica Benidorm, Benidorm, Alicante, Spain. Electronic address: atosrodriguez@gmail.com.
  • Radiation Oncology Department, Hospital Clínica Benidorm, Benidorm, Alicante, Spain.
  • Exercise Intervention for Health Research Group (EXINH-RG), Department of Physiotherapy, University of Valencia, Valencia, Spain.
  • Radiation Oncology Department, Hospital Clínica Benidorm, Benidorm, Alicante, Spain; Radiation Oncology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.
  • Radiation Oncology Department, Hospital Clínica Benidorm, Benidorm, Alicante, Spain; Radiation Oncology Department, Hospital Vithas Virgen del Consuelo, Valencia, Spain.

Zitieren

APA

Rodríguez Villalba, S., Guevara Barrera, D., Suso-Martí, L., Sanchis-Sánchez, E., Pérez-Calatayud, J., Lago Martín, J. D., Blázquez Molina, F., & Santos Ortega, M. (2025). High-dose-rate (2 fractions of 13.5 Gy) and low-dose-rate brachytherapy as monotherapy in prostate cancer. Long term outcomes and predictive value of nadir prostate-specific antigen. Brachytherapy, 24(2), 310-317. https://doi.org/10.1016/j.brachy.2024.10.014

Vancouver

Rodríguez Villalba S, Guevara Barrera D, Suso-Martí L, Sanchis-Sánchez E, Pérez-Calatayud J, Lago Martín JD, et al. High-dose-rate (2 fractions of 13.5 Gy) and low-dose-rate brachytherapy as monotherapy in prostate cancer. Long term outcomes and predictive value of nadir prostate-specific antigen. Brachytherapy. 2025;24(2):310-317. doi:10.1016/j.brachy.2024.10.014

BibTeX
@article{RodrguezVillalba2025,
  author = {Rodríguez Villalba, Silvia and Guevara Barrera, Diana and Suso-Martí, Luis and Sanchis-Sánchez, Enrique and Pérez-Calatayud, Jose and Lago Martín, Jose Domingo and Blázquez Molina, Francisco and Santos Ortega, Manuel},
  title = {High-dose-rate (2 fractions of 13.5 Gy) and low-dose-rate brachytherapy as monotherapy in prostate cancer. Long term outcomes and predictive value of nadir prostate-specific antigen},
  journal = {Brachytherapy},
  year = {2025},
  volume = {24},
  number = {2},
  pages = {310--317},
  doi = {10.1016/j.brachy.2024.10.014}
}
Kostenlos starten →